Ocular surface alteration after long-term treatment with an antiglaucomatous drug
about
Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye dropsIncidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications.Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Ocular lubricant use in medically and surgically treated glaucoma: a retrospective longitudinal analysis.Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy.Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study.Short- and long-term safety of glaucoma drugs.CA 19-9 ELISA test: a new method for studying mucus changes in tears.Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostoneSymptoms and signs of ocular surface disease related to topical medication in patients with glaucomaChallenges in the clinical measurement of ocular surface disease in glaucoma patients.Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients.Limbal Basal Cell Density Decreases in Limbal Stem Cell Deficiency.Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medicationsTrefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery?Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study.Characterization of the Corneal Subbasal Nerve Plexus in Limbal Stem Cell Deficiency.Short-term effect of topical brinzolamide-timolol fixed combination on ocular surface of glaucoma patients.In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis).Influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma.Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: a randomized clinical trial.Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarityAssessment and management of proximal and incomplete symptomatic obstruction of the lacrimal drainage system.Comparative cross-sectional analysis of the effects of topical antiglaucoma drugs on the ocular surface.The tear ferning test: a simple clinical technique to evaluate the ocular tear film.The effect of additional topical cyclosporine or vitamin A on the ocular surface during antiglaucoma medication administration.Effects of antiglaucoma drugs on the ocular surface in rabbits: a fixed-combination drug versus two concomitant drugs.Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK).The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.Effect of timolol with and without preservative on the basal tear turnover in glaucomaThe leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride-induced murine dry eye model.Adverse effects of topical antiglaucomatous medications on the conjunctiva.In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line.Ocular surface disease in patients under topical treatment for glaucoma.The effect of prophylactic topical carbonic anhydrase inhibitors in canine primary closed-angle glaucoma.Chronic progressive conjunctival cicatrisation.Changes in corneal parameters at confocal microscopy in treated glaucoma patients.Ocular Surface Changes in Primary Open Angle Glaucoma with Long Term Topical Anti Glaucoma Medication.
P2860
Q27009083-EF079CDD-2649-4FD2-81FF-06882C54C9C5Q33819802-D28DD69D-BD15-44B1-AEB3-FDC6EBBB007CQ33857744-2F8E0F4D-7510-4F75-83C9-739A52746CD1Q33865232-065E60F8-0914-4E0A-8448-010A830A3BC9Q33914619-64197448-DFA5-4393-82B0-92947D399122Q34678488-824E71CF-B51D-4A74-84A4-7BCF0960D548Q35194520-3B524076-C706-443C-AF96-ED34B33245F7Q35301950-3A5E9304-9836-4C49-AB0E-C9C15A91F384Q35312605-F868BFEA-FDD7-4194-BB2E-D974D36CC18DQ35444198-51D2F75C-6E01-43D5-9D89-38D4BA999381Q35555771-FA23E896-4E38-4C85-B1BA-416489480CC0Q35589561-D10B9A28-E496-4E2E-BBCB-2BDCF5C58CE7Q35639470-18EE4BC8-78DA-4789-AE21-17ADFDA7BB29Q35684820-8EBAB38C-B2DD-4BAA-9C0F-F1559E2DD85CQ35748985-41F5D666-152C-4C37-84B7-7CE8190014F0Q35762703-252D46A0-3873-4FDC-A75B-83C81BA02555Q35865215-DDB09623-D6CE-4E68-9B44-AABF95BA6386Q36219765-D1E35C34-3D96-479C-BC5C-478B64CE51E7Q36490454-DCCA1DC8-74C4-455F-90C5-28F6822FFB27Q36898923-D2839F77-2332-4364-82C7-F94A505E25B2Q37067698-12E6E8DE-6A2E-46E5-9DDD-9B472EE5EB4AQ37185487-D0A21178-23BA-4900-A1CA-2D8409D9E783Q37234164-0080B7C2-B9A0-4CA8-B42A-AC4A5541169BQ37250982-01BF2140-96ED-4068-9985-58BEEC106A7FQ37985858-36E0F779-80AC-494C-8EC7-DAFF6BE1FFB6Q38096951-AB206FA4-7D2F-4038-9D4E-08640530EF91Q38241385-D21045F3-796B-4B51-B072-A923C8A87202Q38462657-1AB2C397-D202-4448-B52A-A1CD39AECA69Q38470550-045A0121-47D3-4CDA-A522-F1408E19AECDQ38843414-DEB4AD1E-B212-43CA-8DB3-009B9E78F564Q39448716-DA615497-B223-4D60-83B7-A4CD8627BB37Q39708297-701B6EB0-5CBB-49FC-A41E-1508E0EA289AQ39820355-EE9CA799-101D-491F-B414-98D335CE0039Q39936116-2829337E-4CCB-43A2-A19A-DBD675E8D4A8Q39993818-3E76428F-72CE-4319-BC0D-168885EC264BQ40204404-F62633C4-4B79-4565-8091-5217F1D7469CQ40580368-5D284E23-A883-4A74-A0CC-267A0D6F9F30Q40773560-80AF6D5D-1E6B-4A25-88CB-A770599FBCA4Q42075931-87C4E1B4-708B-474C-8BED-A4567DF49373Q42209156-61CAB0AC-BC87-4880-BBF1-D399CC8C01AA
P2860
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
description
1992 nî lūn-bûn
@nan
1992 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
@ast
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
@en
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
@nl
type
label
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
@ast
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
@en
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
@nl
prefLabel
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
@ast
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
@en
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
@nl
P2093
P1433
P1476
Ocular surface alteration after long-term treatment with an antiglaucomatous drug
@en
P2093
J C Pastor
J M Herreras
V M Asensio
P304
P356
10.1016/S0161-6420(92)31847-0
P407
P577
1992-07-01T00:00:00Z